Skip to main content

Children's clinical drug trials now mandated in US

A new law in the US requiring new adult drugs to be tested for use in children could result in a three-fold increase in the number of pediatric clinical trials.

Written byJohn Borchardt
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00

HOUSTON. "We have inadequate information regarding the safety and effectiveness of drugs for children. As a result, children have not been equal recipients of the great advances in medicine and drug research," observes Mark S. Schriener, MD, medical director of the Children's Clinical Research Institute, part of the Children's Hospital of Philadelphia "Currently, only about 20% of the drugs on the market are well studied in children," he said. "That will change in December 2000 when a new law goes into effect requiring that all new drugs and new formulations of existing drugs be tested for use in children." The US Food and Drug Administration rule will require any new adult drug that could be used in children with the same disease to undergo pediatric study.

On a national level, some 180 pediatric drug trials are typically running every year. On the basis of the number of drugs approved in ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

Related articles background image
August 2026 Digest cover
August 2026

Epic Fail: Sea-Monkeys Sabotage Fieldwork

When Barry Hicks set out to photograph thrombolites, thousands of unexpected visitors photobombed his underwater images.

View this Issue
Improving rAAV Production for Viral Vector Manufacturing

Improving rAAV Production for Viral Vector Manufacturing

cytiva logo
Advancing Respiratory Immunity Through Tissue-Resident Memory T Cell Research

Advancing Respiratory Immunity Through Tissue-Resident Memory T Cell Research

Miltenyi
Overcoming Immunotherapy Resistance in Liver Cancer

Overcoming Immunotherapy Resistance in Liver Cancer

Axion Biosystems
Optimizing NGS Library Preparation for Reliable Sequencing Data

Optimizing NGS Library Preparation for Reliable Sequencing Data

Covaris

Products

Sino Biological Logo

Sino Biological Launches European Newsletter Campaign with Exclusive Welcome Gifts

Sino Biological Logo

Sino Biological Launches SuperNuclease ® Pro with Free Trial Program

Sino Biological Logo

Sino Biological Launches Precisely Characterized Full-Length p-Tau217 Protein to Advance Next-Generation Alzheimer’s Biomarker Assay Development

A photo of a scientist placing the Resipher device on a 96-well plate.

Resipher: Continuous Live-Cell Mitochondrial Respiration Monitoring in 96-Well Plates

Lucid Scientific logo